WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006089015) METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/089015    International Application No.:    PCT/US2006/005459
Publication Date: 24.08.2006 International Filing Date: 16.02.2006
IPC:
A61K 38/17 (2006.01), A61K 31/517 (2006.01), A61K 39/395 (2006.01)
Applicants: GENENTECH, INC. [US/US]; 1 Dna Way, Ms 49, South San Francisco, California 94080 (US) (For All Designated States Except US).
ASHKENAZI, Avi J. [US/US]; (US) (For US Only)
Inventors: ASHKENAZI, Avi J.; (US)
Agent: MARSCHANG, Diane L.; c/o Genentech, Inc., 1 DNA Way, MS 49, South San Francisco, California 94080 (US)
Priority Data:
11/061,258 18.02.2005 US
Title (EN) METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS
(FR) METHODES D'UTILISATION D'AGONISTES DE RECEPTEURS DE MORT ET D'INHIBITEURS D'EGFR
Abstract: front page image
(EN)Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with EGFR inhibitors, such as TarcevaTM .
(FR)L'invention concerne des méthodes d'utilisation de ligands de récepteurs de mort, tels que des polypeptides ligands APO-2/TRAIL ou des anticorps de récepteurs de mort, ainsi que d'inhibiteurs d'EGFR pour traiter des états pathologiques tels que le cancer. Dans des modes de réalisation, l'invention concerne des méthodes d'utilisation d'Apo2L/TRAIL ou d'anticorps de récepteurs de mort tels que des anticorps DR5 et des anticorps DR4 en combinaison avec des inhibiteurs d'EGFR, tels que TarcevaTM .
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)